borderline significantP =0.06
In addition there was a borderline significant adverse effect for deletion 14q in patients with gain 1q regarding EFS (median of 13 vs . 15 months, P =0.06, Figure 2C ).
In addition there was a borderline significant adverse effect for deletion 14q in patients with gain 1q regarding EFS (median of 13 vs . 15 months, P =0.06, Figure 2C ).